EBQ:Use of Sodium Polystyrene Sulfonate (Kayexylate) in Hyperkalemia

Complete Journal Club Article
Evidence Review. "Use of Sodium Polystyrene Sulfonate (Kayexalate) in Hyperkalemia". Clinical Debate. . :.
PubMed

Clinical Question

Is sodium polystyrene sulfonate (SPS/Kayexalate) effective and safe for the treatment of hyperkalemia?

Conclusion

  • Evidence supporting the efficacy of SPS for acute potassium lowering is extremely limited
  • SPS has significant potential for harm, including intestinal necrosis, particularly when combined with sorbitol
  • Alternative treatments (insulin/glucose, beta-agonists, dialysis) have better evidence and faster onset

Major Points

  • SPS was approved by the FDA in 1958 without modern efficacy studies
  • The only randomized study of SPS (Gruy-Kapral 1998) showed modest potassium reduction but used a small sample
  • Colonic necrosis is a rare but potentially fatal adverse effect, especially with sorbitol co-administration
  • The FDA issued a warning against co-administration of SPS with sorbitol in 2009
  • Newer potassium binders (patiromer, sodium zirconium cyclosilicate) have better evidence for efficacy and safety

Study Design

  • Clinical debate and evidence review of available literature on SPS for hyperkalemia

Population

  • Patients with hyperkalemia (potassium >5.0 mEq/L) requiring potassium lowering

Interventions

  • SPS (Kayexalate) administered orally or rectally, with or without sorbitol
  • Compared to: no SPS, other potassium-lowering therapies, or placebo

Outcomes

  • Limited RCT data: Gruy-Kapral study showed potassium reduction of 0.8 mEq/L over 24 hours
  • Onset of action is slow (hours to days), making it unsuitable for acute hyperkalemia management
  • Case reports of colonic necrosis, particularly with sorbitol combination

Pro Argument

Previous standard of care.

Con Argument

Criticisms

  • The entire evidence base for SPS rests on a single small RCT and decades of clinical tradition
  • FDA approval predated modern drug efficacy requirements
  • SPS is contraindicated in bowel obstruction and should be used with extreme caution post-operatively
  • Onset of action (hours to days) means it has no role in the acute management of life-threatening hyperkalemia
  • Many EM experts have called for abandoning its use entirely in the ED

Funding

  • Not applicable (clinical debate)

Sources

  • Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: Are they safe and effective? J Am Soc Nephrol 21: 733-5, 2010.
  • Scherr L, Ogden DA, Mead AW, et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med 264: 115-9, 1961.
  • Gruy-Kapral C, Emmett M, Santa Ana CA, et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 9: 1924–30, 1998
  • Mahoney BA, Smith WAD, Lo D, et al. Emergency interventions for hyperkalaemia (review). Cochcran Database of Systematic Reviews 2005, issue 3, 2009.
  • Kamel K, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant 18: 2215-8, 2003.
  • Rogers BR, LI SC. Acute colonic necrosis associated with sodium polystyrene sulfonate (kayexalate) enemas in a critically ill patient: Case report and review of the literature. J Trauma 51: 395-7, 2001.
  • Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ 339: 1019-24, 2009.
  • Bomback A, Woosley JT, Kshirsagar AV. Colonic necrosis due to sodium polystyrene sulfate (kayexalate). Am J of EM 27: 753.e1-753.e2, 2009.
  • Welsberg LS. Management of severe hyperkalemia. Crit Care Med 36: 3246-51, 2008.
  • Sood MM, Sood AR, Richardson R. Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia. Mayo Clin Proc 82: 1553-61, 2007

See Also

Obtenido de «https://www.wikem.org/w/index.php?title=EBQ:Use_of_Sodium_Polystyrene_Sulfonate_(Kayexylate)_in_Hyperkalemia&oldid=388433»